menu
    • menu
    [{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALG-000184","moa":"||Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TYK Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"TYK Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TYK Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TYK Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Intas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Intas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Intas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Immunology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Durham VA Health Care System | VA Palo Alto Health Care System | Portland VA Medical Center | VA Puget Sound Health Care System | Michael E. DeBakey VA Medical Center | VA Boston Healthcare System | North Texas Veterans Healthcare System | VA Ann Arbor He","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ Durham VA Health Care System | VA Palo Alto Health Care System | Portland VA Medical Center | VA Puget Sound Health Care System | Michael E. DeBakey VA Medical Center | VA Boston Healthcare System | North Texas Veterans Healthcare System | VA Ann Arbor He","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ Durham VA Health Care System | VA Palo Alto Health Care System | Portland VA Medical Center | VA Puget Sound Health Care System | Michael E. DeBakey VA Medical Center | VA Boston Healthcare System | North Texas Veterans Healthcare System | VA Ann Arbor He"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Inhibitor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Inhibitor Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Inhibitor Therapeutics"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pulmatrix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Undisclosed"},{"orgOrder":0,"company":"Inhibitor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itraconazole","moa":"||Cytochrome P450 51","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibitor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibitor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibitor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Cipla","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Cipla"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Undisclosed"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"KBP Biosciences \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"KBP Biosciences \/ Covance"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Syneos Health | Cambridge Cognition","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emalex Bioscience \/ Syneos Health | Cambridge Cognition","highestDevelopmentStatusID":"6","companyTruncated":"Emalex Bioscience \/ Syneos Health | Cambridge Cognition"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"George R Thompson","sponsor":"Mayne Pharma Do Brasil Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"George R Thompson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"George R Thompson \/ Mayne Pharma Do Brasil Ltda","highestDevelopmentStatusID":"8","companyTruncated":"George R Thompson \/ Mayne Pharma Do Brasil Ltda"}]

    Find Clinical Drug Pipeline Developments & Deals for Itraconazole, Sporanox

    Menu

    Itraconazole, Sporanox

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aligos Therapeutics

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed

                            Aligos Therapeutics

                            U.S.A arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALG-000184,Carbamazepine,Itraconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

                            Details : ALG-000184 is a potent potential best/first-in-class oral small molecule capsid assembly modulator (CAM-E) being developed for chronic hepatitis B.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 22, 2024

                            Lead Product(s) : ALG-000184,Carbamazepine,Itraconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bristol Myers Squibb

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on ...

                            Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2024

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shenzhen TargetRx

                            China arrow
                            OPRD
                            Not Confirmed

                            Shenzhen TargetRx

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TGRX-326 Pharmacokinetic Drug Interaction

                            Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2024

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TYK Medicines

                            China arrow
                            OPRD
                            Not Confirmed

                            TYK Medicines

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Hea...

                            Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 13, 2024

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pulmatrix

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Cipla

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Pulmatrix Stops PUR1900 Phase 2B Enrollment To Preserve Cash

                            Details : Under the amendment, Cipla and Pulmatrix agreed to halt patient enrollment in the Ph2b study of PUR1900 (itraconazole) at 8 subjects, with Cipla assuming sole responsibility for its development.

                            Product Name : Pulmazole

                            Product Type : Miscellaneous

                            Upfront Cash : $22.0 million

                            January 08, 2024

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Cipla

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Emalex Bioscience

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Emalex Bioscience

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Syneos Health | Cambridge Cognition

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug Interaction Study

                            Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 08, 2024

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Syneos Health | Cambridge Cognition

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Johns Hopkins University

                            Country arrow
                            OPRD
                            Not Confirmed

                            Johns Hopkins University

                            Country arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inhibitor Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

                            Details : Under the agreement, Inhibitor Therapeutics licenses U.S Patent for New Angiogenesis Inhibitors from JHU, for use of SUBA-Cap (itraconazole) in Prostate Cancer, Basal Cell Carcinoma including Basal Cell Carcinoma Nevus Syndrome (an orphan oncology diseas...

                            Product Name : SUBA-Cap

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inhibitor Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Jiangsu Hengrui Medicine

                            China arrow
                            OPRD
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Effect of Itraconazole on Pharmacokinetics (PK) of SHR8554 in Healthy Adult Subjects

                            Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Innovent Biologics

                            China arrow
                            OPRD
                            Not Confirmed

                            Innovent Biologics

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of IBI351 in Healthy Subjects

                            Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 26, 2023

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pulmatrix

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Pulmatrix

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

                            Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 28, 2022

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth